Neurocrine Biosciences Inc (NASDAQ: NBIX)

$130.14 ▼ -1.04 (-0.79%)

As of Apr 23, 2026 01:49 PM

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0000914475

Market Cap 12.96 Bn

P/E 27.02

P/S 4.53

Div. Yield 0.00

ROIC (Qtr) 0.13

Revenue Growth (1y) (Qtr) 28.33

Add ratio to table...

About

Neurocrine Biosciences Inc focuses on the development and commercialization of therapies for neurological and psychiatric disorders, operating within the biopharmaceutical industry. The company specializes in creating innovative treatments that address complex conditions, leveraging its expertise in neuroscience to improve patient outcomes. Its primary products include INGREZZA and CRENESSITY, which are designed to treat movement disorders and other neurological conditions, reflecting its commitment to advancing therapeutic solutions in these areas. Neurocrine...

Neurocrine Biosciences Inc focuses on the development and commercialization of therapies for neurological and psychiatric disorders, operating within the biopharmaceutical industry. The company specializes in creating innovative treatments that address complex conditions, leveraging its expertise in neuroscience to improve patient outcomes. Its primary products include INGREZZA and CRENESSITY, which are designed to treat movement disorders and other neurological conditions, reflecting its commitment to advancing therapeutic solutions in these areas.

Neurocrine Biosciences generates revenue through the sales of its proprietary pharmaceutical products, primarily targeting patients suffering from neurological and psychiatric disorders. INGREZZA, a key product, is used to treat tardive dyskinesia, a condition characterized by involuntary movements, while CRENESSITY is aimed at addressing other neurological conditions. The company's customer base includes healthcare providers, hospitals, and patients who benefit from these specialized treatments, with a focus on improving quality of life for individuals with complex medical needs.

• INGREZZA: This product is a treatment for tardive dyskinesia, a movement disorder characterized by involuntary movements. It caters to patients suffering from this condition, providing a therapeutic option to manage symptoms and improve daily functioning.

• CRENESSITY: This product is designed to address other neurological conditions, though specific details about its exact indications are not provided. It represents the company's efforts to expand its portfolio and meet the needs of a broader patient population.

Neurocrine Biosciences holds a significant position within the biopharmaceutical industry, particularly in the niche of neurological and psychiatric treatments. The company competes with other biopharmaceutical firms that focus on similar therapeutic areas, though specific competitors are not mentioned in the provided document. Its competitive advantages include a strong research and development pipeline, a commitment to innovation, and a focus on addressing unmet medical needs in the neuroscience field. These factors position the company as a leader in developing and commercializing therapies for complex neurological and psychiatric disorders.

The company's customer base includes healthcare providers, hospitals, and patients who rely on its specialized treatments for neurological and psychiatric conditions. While specific customer names are not disclosed, the general customer base consists of individuals and institutions seeking effective therapies to manage these complex medical needs. Neurocrine Biosciences' products are designed to improve patient outcomes and quality of life, reflecting its dedication to advancing therapeutic solutions in the biopharmaceutical industry.

Investment thesis

Bull case

Neurocrine’s first two commercial assets, INGREZZA and CRENESSITY, are positioned for continued high‑growth trajectories that have historically exceeded market expectations. INGREZZA’s 10‑year exclusivity window, combined with a robust sales‑force expansion and deep‑rooted formulary access investments, should sustain double‑digit volume growth that has already translated into 22% revenue acceleration in 2025. The company’s guidance of $2.7–$2.8 billion in 2026, reflecting a 10% sales increase, signals strong confidence in the continued demand from the remaining 9 out of 10 TD/HD patients who are yet to switch to a VMAT2 inhibitor. This volume‑driven model, underpinned by a historically low net‑pricing erosion, creates a scalable revenue engine that can support further product launches.
CRENESSITY’s first‑in‑disease launch has already captured 10% of the classic CAH patient population in its inaugural year, a milestone that the company frames as the groundwork for blockbuster status. The drug’s favorable safety profile, demonstrated durability in a two‑year open‑label extension, and its ability to reduce glucocorticoid exposure address a critical unmet need that has traditionally been managed with suboptimal glucocorticoid regimens. With a projected market of roughly 20,000 untreated U.S. patients and a clear opportunity to penetrate additional prescriber segments beyond endocrinology (via AI‑driven provider targeting), CRENESSITY offers a clear path to reach 20–30% of the treatable population within 3–5 years. The company’s strategic investment in medical education and the support of patient advocacy groups further accelerates adoption, suggesting a self‑reinforcing growth cycle.
Neurocrine’s long‑standing experience in VMAT2 biology positions it as a category leader, and its pipeline of next‑generation VMAT2 inhibitors—NBI‑890 and NBI‑675—builds on the proven receptor‑occupancy advantage that INGREZZA already demonstrated in a head‑to‑head PET study against Austedo XR. The company’s intent to develop long‑acting injectable formulations could capture non‑compliant or refractory patients, expanding the addressable market beyond the current prescription base. Moreover, the high target occupancy data suggest that these new molecules may deliver superior clinical outcomes, potentially cementing a dominant market share once regulatory approval is secured. If the Phase II studies in tardive dyskinesia complete favorably in 2026–27, Neurocrine could secure a new blockbuster pipeline that leverages its established commercial infrastructure.
The CRF platform, long a cornerstone of Neurocrine’s research heritage, is being revitalized through NBIP‑1435 for classic CAH and NBIP‑2118 for metabolic disorders such as obesity. These agents tap into sizable therapeutic windows: the obesity market is projected to grow at 7% CAGR over the next decade, and the first‑in‑class profile of a CRF2 agonist could position Neurocrine as a leader in an area with limited pharmacologic options. By integrating a disease‑specific indication with a broader metabolic indication, the company is diversifying risk and creating multiple revenue streams that are insulated from the rare‑disease dynamics of INGREZZA and CRENESSITY. This structural shift enhances the company’s resilience against the typical volatility seen in orphan drug markets.
Neurocrine’s balance sheet remains exceptionally robust, with $2.5 billion in cash and a 30% non‑GAAP operating margin, which affords the company significant flexibility to fund aggressive commercial expansion and pipeline development without jeopardizing liquidity. The high margin reflects efficient manufacturing and a focus on high‑value, low‑volume drugs that keep costs manageable. The company’s strategy of reinvesting a modest portion of cash into R&D (mid‑30% of sales) signals a disciplined approach that balances short‑term profitability with long‑term growth potential. Such financial stability positions Neurocrine to weather competitive pressure and potential pricing adjustments while still executing on its pipeline and commercial plans.

Neurocrine’s first two commercial assets, INGREZZA and CRENESSITY, are positioned for continued high‑growth trajectories that have historically exceeded market expectations. INGREZZA’s 10‑year exclusivity window, combined with a robust sales‑force expansion and deep‑rooted formulary access investments, should sustain double‑digit volume growth that has already translated into 22% revenue acceleration in 2025. The company’s guidance of $2.7–$2.8 billion in 2026, reflecting a 10% sales increase, signals strong confidence in the continued demand from the remaining 9 out of 10 TD/HD patients who are yet to switch to a VMAT2 inhibitor. This volume‑driven model, underpinned by a historically low net‑pricing erosion, creates a scalable revenue engine that can support further product launches.
CRENESSITY’s first‑in‑disease launch has already captured 10% of the classic CAH patient population in its inaugural year, a milestone that the company frames as the groundwork for blockbuster status. The drug’s favorable safety profile, demonstrated durability in a two‑year open‑label extension, and its ability to reduce glucocorticoid exposure address a critical unmet need that has traditionally been managed with suboptimal glucocorticoid regimens. With a projected market of roughly 20,000 untreated U.S. patients and a clear opportunity to penetrate additional prescriber segments beyond endocrinology (via AI‑driven provider targeting), CRENESSITY offers a clear path to reach 20–30% of the treatable population within 3–5 years. The company’s strategic investment in medical education and the support of patient advocacy groups further accelerates adoption, suggesting a self‑reinforcing growth cycle.
Neurocrine’s long‑standing experience in VMAT2 biology positions it as a category leader, and its pipeline of next‑generation VMAT2 inhibitors—NBI‑890 and NBI‑675—builds on the proven receptor‑occupancy advantage that INGREZZA already demonstrated in a head‑to‑head PET study against Austedo XR. The company’s intent to develop long‑acting injectable formulations could capture non‑compliant or refractory patients, expanding the addressable market beyond the current prescription base. Moreover, the high target occupancy data suggest that these new molecules may deliver superior clinical outcomes, potentially cementing a dominant market share once regulatory approval is secured. If the Phase II studies in tardive dyskinesia complete favorably in 2026–27, Neurocrine could secure a new blockbuster pipeline that leverages its established commercial infrastructure.
The CRF platform, long a cornerstone of Neurocrine’s research heritage, is being revitalized through NBIP‑1435 for classic CAH and NBIP‑2118 for metabolic disorders such as obesity. These agents tap into sizable therapeutic windows: the obesity market is projected to grow at 7% CAGR over the next decade, and the first‑in‑class profile of a CRF2 agonist could position Neurocrine as a leader in an area with limited pharmacologic options. By integrating a disease‑specific indication with a broader metabolic indication, the company is diversifying risk and creating multiple revenue streams that are insulated from the rare‑disease dynamics of INGREZZA and CRENESSITY. This structural shift enhances the company’s resilience against the typical volatility seen in orphan drug markets.
Neurocrine’s balance sheet remains exceptionally robust, with $2.5 billion in cash and a 30% non‑GAAP operating margin, which affords the company significant flexibility to fund aggressive commercial expansion and pipeline development without jeopardizing liquidity. The high margin reflects efficient manufacturing and a focus on high‑value, low‑volume drugs that keep costs manageable. The company’s strategy of reinvesting a modest portion of cash into R&D (mid‑30% of sales) signals a disciplined approach that balances short‑term profitability with long‑term growth potential. Such financial stability positions Neurocrine to weather competitive pressure and potential pricing adjustments while still executing on its pipeline and commercial plans.

Bear case

While Neurocrine’s commercial and pipeline narratives are compelling, the company’s heavy reliance on large SG&A spend—forecasted at 40% of sales for 2026—raises concerns about cost sustainability if growth does not materialize at the projected pace. The aggressive sales force expansion, especially for CRENESSITY, could dilute the effectiveness of each representative and result in diminishing returns if prescriber engagement does not translate into incremental prescriptions. Moreover, the high cost of field expansion coupled with the inherent uncertainties of a rare disease market may strain operating margins and limit the company's ability to reinvest in other strategic initiatives.
The lack of concrete pricing guidance for CRENESSITY reflects underlying uncertainty about market acceptance and payer dynamics. Without a clear revenue forecast, investors must rely on anecdotal evidence of uptake and prescriber enthusiasm, which may overstate true commercial potential. Additionally, the company’s reliance on a 10% market penetration metric—based on an estimate of 20,000 U.S. CAH patients—does not account for the complexities of diagnosing and treating a disease that often goes undetected, meaning the actual addressable population could be larger or smaller than projected. This ambiguity undermines the robustness of the revenue upside narrative.
The imminent entry of Austedo XR, a deuterated tetrabenazine with a negotiated price, poses a significant competitive threat that could erode INGREZZA’s market share. The company’s own head‑to‑head PET study, while demonstrating higher target occupancy, does not guarantee superior clinical outcomes or payer preference, especially if Austedo’s price advantage translates into better formulary positioning. A shift toward a more price‑sensitive environment could compress net pricing and reduce margins, counteracting the projected 10% sales growth. In such a scenario, the company would face a double whammy of price erosion and increased competition.
Neurocrine’s pipeline is heavily weighted toward Phase III studies with data readouts scheduled for 2027, creating a concentration of risk in a single year. The success of osavampator and direclidine remains unproven, and regulatory setbacks or negative trial outcomes could have a catastrophic impact on investor sentiment and the company’s valuation. Furthermore, the company’s strategy of “data‑rich” readouts may create high expectations that, if unmet, could lead to a sharp correction in stock price, regardless of the long‑term therapeutic potential.
The CRF platform, while scientifically promising, faces an uncertain regulatory pathway that may delay approvals and limit commercialization. The proposed NBIP‑2118 for obesity, for example, competes in a crowded market where safety concerns (e.g., central nervous system side effects) and modest efficacy could hinder adoption. The company’s reliance on a single class of novel therapeutics (CRF antagonists/agonists) introduces a concentration risk that could be detrimental if the platform fails to differentiate effectively from competitors or faces unforeseen safety signals.

While Neurocrine’s commercial and pipeline narratives are compelling, the company’s heavy reliance on large SG&A spend—forecasted at 40% of sales for 2026—raises concerns about cost sustainability if growth does not materialize at the projected pace. The aggressive sales force expansion, especially for CRENESSITY, could dilute the effectiveness of each representative and result in diminishing returns if prescriber engagement does not translate into incremental prescriptions. Moreover, the high cost of field expansion coupled with the inherent uncertainties of a rare disease market may strain operating margins and limit the company's ability to reinvest in other strategic initiatives.
The lack of concrete pricing guidance for CRENESSITY reflects underlying uncertainty about market acceptance and payer dynamics. Without a clear revenue forecast, investors must rely on anecdotal evidence of uptake and prescriber enthusiasm, which may overstate true commercial potential. Additionally, the company’s reliance on a 10% market penetration metric—based on an estimate of 20,000 U.S. CAH patients—does not account for the complexities of diagnosing and treating a disease that often goes undetected, meaning the actual addressable population could be larger or smaller than projected. This ambiguity undermines the robustness of the revenue upside narrative.
The imminent entry of Austedo XR, a deuterated tetrabenazine with a negotiated price, poses a significant competitive threat that could erode INGREZZA’s market share. The company’s own head‑to‑head PET study, while demonstrating higher target occupancy, does not guarantee superior clinical outcomes or payer preference, especially if Austedo’s price advantage translates into better formulary positioning. A shift toward a more price‑sensitive environment could compress net pricing and reduce margins, counteracting the projected 10% sales growth. In such a scenario, the company would face a double whammy of price erosion and increased competition.
Neurocrine’s pipeline is heavily weighted toward Phase III studies with data readouts scheduled for 2027, creating a concentration of risk in a single year. The success of osavampator and direclidine remains unproven, and regulatory setbacks or negative trial outcomes could have a catastrophic impact on investor sentiment and the company’s valuation. Furthermore, the company’s strategy of “data‑rich” readouts may create high expectations that, if unmet, could lead to a sharp correction in stock price, regardless of the long‑term therapeutic potential.
The CRF platform, while scientifically promising, faces an uncertain regulatory pathway that may delay approvals and limit commercialization. The proposed NBIP‑2118 for obesity, for example, competes in a crowded market where safety concerns (e.g., central nervous system side effects) and modest efficacy could hinder adoption. The company’s reliance on a single class of novel therapeutics (CRF antagonists/agonists) introduces a concentration risk that could be detrimental if the platform fails to differentiate effectively from competitors or faces unforeseen safety signals.

Product and Service Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ZTS	Zoetis Inc.	52.41 Bn	19.60	5.54	9.04 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.83 Bn	25.23	2.08	16.81 Bn
3	UTHR	UNITED THERAPEUTICS Corp	25.40 Bn	19.03	7.98	-
4	NBIX	Neurocrine Biosciences Inc	12.96 Bn	27.02	4.53	-
5	HCM	HUTCHMED (China) Ltd	12.76 Bn	28.06	23.27	0.09 Bn
6	ELAN	Elanco Animal Health Inc	11.22 Bn	-48.11	2.38	4.02 Bn
7	ALKS	Alkermes plc.	5.52 Bn	22.80	3.74	-
8	LNTH	Lantheus Holdings, Inc.	5.51 Bn	23.64	3.57	0.57 Bn

Research Tools